Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Multiple gene-deletion vaccinia virus Tiantan strain against mpox.
Virol J
January 2025
Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, 130122, People's Republic of China.
Monkeypox virus (MPXV) is an important zoonotic pathogenic virus, which poses serious threats to public health. MPXV infection can be prevented by immunization against the variola virus. Because of the safety risks and side effects of vaccination with live vaccinia virus (VACV) strain Tian Tan (VTT), we constructed two gene-deleted VTT recombinants (TTVAC7 and TTVC5).
View Article and Find Full Text PDFComprehensive Insights into Monkeypox (mpox): Recent Advances in Epidemiology, Diagnostic Approaches and Therapeutic Strategies.
Pathogens
December 2024
Center for General Education, National Chung Hsing University, Taichung 402, Taiwan.
Monkeypox (mpox) is a viral infection closely related to smallpox, manifesting as a milder febrile rash in affected individuals. Over the past two decades, the incidence of mpox has surged, possibly linked to a declining immunity against the smallpox vaccine worldwide. Recent outbreaks of mpox in multiple countries have sparked concerns regarding altered transmission patterns and the potential for a global menace.
View Article and Find Full Text PDFDynamic analysis and optimal control of a hybrid fractional monkeypox disease model in terms of external factors.
Sci Rep
January 2025
Department of Mathematics and Statistics, College of Science, Taif University, P.O. Box 11099, 21944, Taif, Saudi Arabia.
The monkeypox virus (MPXV), which is a member of the Orthopoxvirus genus in the class Poxviridae, is the causative agent of the zoonotic viral infection MPXV. The disease is similar to smallpox, but it is usually less dangerous. This study examines the evolution of the MPXV epidemic in Canada with an emphasis on the effects of control employing actual data.
View Article and Find Full Text PDFEurope previously approved tecovirimat for mpox, based on animal data; the U.S. has stockpiled it for smallpox.
View Article and Find Full Text PDF"If that would have lessened my symptoms, that would have been great...": a qualitative study about the acceptability of tecovirimat as treatment for mpox.
BMC Med
January 2025
Health Emergencies Programme, World Health Organization, Geneva, Switzerland.
Background: Tecovirimat, an antiviral treatment for smallpox, was approved as a treatment for mpox by the European Medicines Agency in January 2022. Approval was granted under "exceptional circumstances" based on effectiveness found in pre-clinical challenge studies in animals and safety studies in humans showing minimal side effects. As clinical efficacy studies are still ongoing, there is currently limited information with regard to the acceptability of tecovirimat to treat mpox.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!